PEN250117P260000
- 18.40
- 0.000.00%
Penumbra Newsroom
RBC Capital Maintains Penumbra(PEN.US) With Buy Rating, Raises Target Price to $285
Penumbra Is Maintained at Buy by Truist Securities
Truist Securities Adjusts Price Target on Penumbra to $285 From $240, Keeps Buy Rating
Truist Financial Maintains Penumbra(PEN.US) With Buy Rating, Raises Target Price to $285
Oppenheimer Maintains Penumbra(PEN.US) With Buy Rating, Maintains Target Price $275
Penumbra Initiated at Outperform by Oppenheimer
Penumbra Analyst Ratings
Oppenheimer Initiates Penumbra(PEN.US) With Buy Rating, Announces Target Price $275
Citi Maintains Penumbra(PEN.US) With Hold Rating, Raises Target Price to $245
Wells Fargo Upgrades Penumbra to Overweight From Equalweight, Price Target Is $190
Wells Fargo Maintains Penumbra(PEN.US) With Buy Rating, Cuts Target Price to $275
Positive Outlook for Penumbra: Buy Rating Driven by THUNDER Trial Success and Market Growth Prospects
Penumbra Is Maintained at Buy by Canaccord Genuity
Penumbra Analyst Ratings
CCORF Maintains Penumbra(PEN.US) With Buy Rating, Raises Target Price to $323
Leerink Partners Sticks to Their Buy Rating for Penumbra (PEN)
Penumbra Is Maintained at Buy by BTIG
Penumbra Analyst Ratings
BTIG Maintains Penumbra(PEN.US) With Buy Rating, Raises Target Price to $270
Cautious Hold Recommendation Amid Uncertainty Following FDA Clearance of Penumbra's Element Vascular Access System